Current management of gout in patients unresponsive or allergic to allopurinol
- 1 November 2004
- journal article
- review article
- Published by Elsevier BV in Joint Bone Spine
- Vol. 71 (6), 481-485
- https://doi.org/10.1016/j.jbspin.2004.07.006
Abstract
The manifestations of gout can be abolished permanently by lifelong urate-lowering therapy maintaining serum urate levels under 360 mmol/l, as this ensures dissolution of pathogenic crystals of monosodium urate monohydrate. Benzbromarone has been withdrawn from the market, leaving allopurinol as the only urate-lowering drug readily available in France. Allopurinol may induce unacceptable side effects, and in patients with dose-limiting renal failure it may not be sufficiently effective. Because allopurinol can induce serious side effects when given concomitantly with purine antimetabolites, it is contraindicated in organ transplant recipients. In patients who cannot tolerate allopurinol, dietary treatment, discontinuation of diuretic agents, and use of losartan or fenofibrate to treat concomitant hypertension or dyslipidemia, respectively, may ensure adequate control of serum urate levels. Desensitization to allopurinol can be attempted in patients with mild cutaneous hypersensitivity reactions but is difficult to perform and rarely used. Uricosuric agents may be helpful in patients with normal or diminished urate excretion. Probenecid is available in France from hospital pharmacies, and benzbromarone can be prescribed via a time-limited authorization procedure. Rasburicase, an Aspergillus urate oxidase produced by genetic engineering, is indicated to prevent acute hyperuricemia induced by chemotherapy for hematological malignancies. Factors that limit the use of rasburicase include the absence of a marketing authorization, the need for parenteral administration, and the absence of validated treatment schedules. Patients with renal failure precluding the use of effective allopurinol dosages are good candidates for benzbromarone therapy. Organ transplant recipients can be given benzbromarone, within the current restrictions to its use; alternatively, mycophenolate mofetil can be substituted for calcineurin inhibitors, which elevate serum urate levels, or for azathioprine, which contraindicates the use of allopurinol.Keywords
This publication has 28 references indexed in Scilit:
- Alcohol intake and risk of incident gout in men: a prospective studyThe Lancet, 2004
- Purine-Rich Foods, Dairy and Protein Intake, and the Risk of Gout in MenNew England Journal of Medicine, 2004
- GoutNew England Journal of Medicine, 2003
- Fenofibrate and losartanAnnals Of The Rheumatic Diseases, 2003
- Long-term remission from gout associated with fenofibrate therapyClinical Rheumatology, 2003
- Relation between adverse events associated with allopurinol and renal function in patients with goutAnnals Of The Rheumatic Diseases, 2001
- Guillain-Barré Syndrome and Allopurinol-Induced HypersensitivityEuropean Neurology, 2001
- Treatment of Chronic Gout in Patients with Renal Function Impairment An Open, Randomized, Actively Controlled StudyJCR: Journal of Clinical Rheumatology, 1999
- Severe allopurinol toxicityAmerican Journal Of Medicine, 1984
- Uricosuric Drugs, with Special Reference to Probenecid and SulfinpyrazoneAdvances in Pharmacology, 1966